# Phase 2 Combination of Melphalan/HDS Via PHP + Tebentafusp in Treating Metastatic Uveal Melanoma

> **NCT07276386** · PHASE2 · RECRUITING · sponsor: **H. Lee Moffitt Cancer Center and Research Institute** · enrollment: 18 (estimated)

## Conditions studied

- Metastatic Uveal Melanoma

## Interventions

- **DRUG:** Melphalan/HDS (Percutaneous Hepatic Perfusion)
- **DRUG:** Tebentafusp

## Key facts

- **NCT ID:** NCT07276386
- **Lead sponsor:** H. Lee Moffitt Cancer Center and Research Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-12-31
- **Primary completion:** 2030-12
- **Final completion:** 2030-12
- **Target enrollment:** 18 (ESTIMATED)
- **Last updated:** 2026-03-31

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07276386

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07276386, "Phase 2 Combination of Melphalan/HDS Via PHP + Tebentafusp in Treating Metastatic Uveal Melanoma". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07276386. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*